Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

1.

Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.

Yee LJ, Im K, Wahed AS, Bugawan T, Li J, Rhodes SL, Erlich H, Rosen HR, Liang TJ, Yang H; Virahep-C Study.

Antimicrob Agents Chemother. 2009 Feb;53(2):615-21. doi: 10.1128/AAC.00947-08. Epub 2008 Oct 13.

PMID:
18852273
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.

Rhodes SL, Erlich H, Im KA, Wang J, Li J, Bugawan T, Jeffers L, Tong X, Su X, Rosen HR, Yee LJ, Liang TJ, Yang H; Virahep-C Study Group.

Genes Immun. 2008 Jun;9(4):328-33. doi: 10.1038/gene.2008.21. Epub 2008 Apr 17.

PMID:
18418397
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
[PubMed - indexed for MEDLINE]
4.

Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.

Hoofnagle JH, Wahed AS, Brown RS Jr, Howell CD, Belle SH; Virahep-C Study Group.

J Infect Dis. 2009 Apr 15;199(8):1112-20. doi: 10.1086/597384.

PMID:
19284286
[PubMed - indexed for MEDLINE]
Free Article
5.

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A.

Ann Intern Med. 2009 Apr 21;150(8):528-40.

PMID:
19380853
[PubMed - indexed for MEDLINE]
6.

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.

de Rueda PM, López-Nevot MÁ, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J.

Am J Gastroenterol. 2011 Jul;106(7):1246-54. doi: 10.1038/ajg.2011.82. Epub 2011 Jun 14.

PMID:
21670772
[PubMed - indexed for MEDLINE]
7.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.

Clin Infect Dis. 2009 Apr 15;48(8):1152-9. doi: 10.1086/597470. Erratum in: Clin Infect Dis. 2009 Aug 1;49(3):489.

PMID:
19275492
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.

Njouom R, Sartre MT, Timba I, Nerrienet E, Tchendjou P, Pasquier C, Rousset D.

J Med Virol. 2008 Dec;80(12):2079-85. doi: 10.1002/jmv.21319.

PMID:
19040282
[PubMed - indexed for MEDLINE]
9.

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.

Gastroenterology. 2009 Feb;136(2):496-504.e3. doi: 10.1053/j.gastro.2008.10.049. Epub 2008 Oct 29.

PMID:
19084016
[PubMed - indexed for MEDLINE]
10.

Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.

Nomura H, Miyagi Y, Tanimoto H, Ishibashi H.

J Viral Hepat. 2009 May;16(5):346-51. doi: 10.1111/j.1365-2893.2009.01099.x. Epub 2009 Feb 12.

PMID:
19222743
[PubMed - indexed for MEDLINE]
11.

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source.

McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D.

Hepatology. 2004 Jul;40(1):108-14.

PMID:
15239092
[PubMed - indexed for MEDLINE]
12.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
[PubMed - indexed for MEDLINE]
13.

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.

Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E; Nagano Interferon Treatment Research Group.

Hepatology. 2008 Dec;48(6):1753-60. doi: 10.1002/hep.22543.

PMID:
18925643
[PubMed - indexed for MEDLINE]
14.

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.

El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK.

J Med Virol. 2009 Sep;81(9):1576-83. doi: 10.1002/jmv.21570.

PMID:
19626613
[PubMed - indexed for MEDLINE]
15.

Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin.

Varghese R, Al-Khaldi J, Asker H, Fadili AA, Al Ali J, Hassan FA.

Hepatogastroenterology. 2009 Jan-Feb;56(89):218-22.

PMID:
19453061
[PubMed - indexed for MEDLINE]
16.

Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Maekawa S, Enomoto N.

J Gastroenterol. 2009;44(10):1009-15. doi: 10.1007/s00535-009-0126-7. Review.

PMID:
19756352
[PubMed - indexed for MEDLINE]
17.

Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.

Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H.

J Gastroenterol. 2009;44(4):338-45. doi: 10.1007/s00535-009-0008-z. Epub 2009 Mar 10.

PMID:
19277449
[PubMed - indexed for MEDLINE]
18.

Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.

Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G.

Clin Infect Dis. 2009 Aug 15;49(4):498-506. doi: 10.1086/600887.

PMID:
19591593
[PubMed - indexed for MEDLINE]
Free Article
19.

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22.

PMID:
19552663
[PubMed - indexed for MEDLINE]
20.

Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.

Kim SR, Imoto S, Mita K, Taniguchi M, Sasase N, Muramatsu A, Kudo M, Kitai S, El-Shamy A, Hotta H, Hayashi Y.

Digestion. 2009;79(1):36-9. doi: 10.1159/000203639. Epub 2009 Feb 25.

PMID:
19246919
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk